In this study, we used the cytogenetic data from CML study IV to investigate incidences of newly arising unbalanced ACA and blast crises under IM long-term treatment with regard to the p210BCR-ABL breakpoint variants b2a2 and b3a2. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.